Fisher & Paykel Healthcare Stock - Analyst consensus and earnings outlook in focus
21.06.2026 - 22:22:50 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 20:20 UTC. Details in the imprint.
Fisher & Paykel Healthcare (NZFAPE0001S2) is trading in a relatively quiet news phase after its recent full-year results and guidance update. With no new ad-hoc releases or rating changes from major houses today, the focus shifts to analyst consensus and the earnings calendar.
All news and key data on Fisher & Paykel Healthcare stock
Background, price data, and regulatory releases on Fisher & Paykel Healthcare stock can be found in the ad-hoc-news topic overview and on the company's investor-relations pages.
What recent results showed
Fisher & Paykel Healthcare, based in Auckland, reported its results for the financial year ended 03/31/2025 in May, showing revenue broadly in line with market expectations and a continued normalization after the pandemic-driven peaks in respiratory-care demand.
According to the company's full-year earnings materials, operating revenue for the 2024/25 year was around NZD 1.7 billion, with hospital product sales remaining the largest contributor and homecare products also delivering steady growth as demand for obstructive sleep apnea treatment devices remained solid.
Analyst views and consensus
Data compiled by market platforms tracking the stock indicate that a majority of covering analysts currently rate Fisher & Paykel Healthcare stock in the Hold to Buy range, with only a small minority on the Sell side, reflecting a broadly constructive but valuation-aware stance.
Consensus estimates point to mid-single-digit to low double-digit percentage revenue growth for the coming financial year, driven mainly by new product penetration in hospital respiratory care and ongoing adoption of homecare humidification systems in key markets such as North America and Europe.
Earnings calendar and guidance focus
After the May full-year release, the next major scheduled event is expected to be the company's interim results for the first half of its 2025/26 financial year, typically reported around late November based on its historical reporting pattern.
Management's guidance accompanying the last earnings release emphasized disciplined operating-expense control and continued investment in research and development, with a medium-term ambition to lift operating margins as volumes scale and manufacturing efficiency programs in New Zealand and Mexico gain traction.
How valuation looks today
On recent prices, Fisher & Paykel Healthcare shares trade at a price-to-earnings multiple above the wider medical-equipment peer average, which reflects the market's expectation for structurally higher growth and robust profitability in its specialized respiratory-care niche.
For retail investors, the key debate in analyst reports is whether that valuation premium is justified by the company's innovation pipeline, margins, and geographic expansion plans, especially as post-pandemic demand patterns in hospital respiratory care continue to normalize.
The product behind the stock
Fisher & Paykel Healthcare generates most of its revenue from hospital respiratory-care systems such as the Optiflow nasal high-flow therapy range, along with homecare products for obstructive sleep apnea and chronic respiratory conditions; both segments rely on proprietary humidification and breathing-circuit technologies.
Where the stock trades today
The shares of Fisher & Paykel Healthcare (NZFAPE0001S2) trade on the New Zealand Exchange (NZX) at NZD 30.00 as of 06/21/2026, 20:00 NZST.
Key facts on Fisher & Paykel Healthcare stock
- Company: Fisher & Paykel Healthcare Corp Ltd
- ISIN: NZFAPE0001S2
- WKN: 884288
- Ticker: FPH
- Venue: NZX
- Price (as of 06/21/2026, 20:00 NZST): 30.00 NZD
- Market cap: 17,000,000,000 NZD (as of 06/21/2026)
- Sector / Industry: Health Care / Medical Equipment
- Index membership: S&P/NZX 50 Index
- Next earnings date: 11/27/2026 (expected interim results)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
